Stock Market Reviews

Read and share opinions on IDYA (IDEAYA Biosciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 4, 2025
• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  Oct 31, 2025
• IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
  Oct 27, 2025
• IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
  Oct 20, 2025
• Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA)
  Oct 18, 2025
• J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA)
  Oct 8, 2025
• Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating
  Sep 10, 2025
• IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
  Sep 8, 2025
• Ideaya Biosciences Says Darovasertib Data Show Tumor Shrinkage in Phase 2 Eye Cancer Trial
  Sep 8, 2025
• IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
  Sep 8, 2025
• IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
  Sep 7, 2025
• IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
  Sep 4, 2025
• IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
  Sep 3, 2025
• Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
  Sep 2, 2025
• IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
  Aug 29, 2025
• IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
  Aug 25, 2025